ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

Gao, Guanghui; Ni, Jian; Wang, Yina; Ren, Shengxiang; Liu, Zhihua; Chen, Gongyan; Gu, Kangsheng; Zang, Aimin; Zhao, Jun; Guo, Renhua; He, Jianxing; Lin, Xiaoyan; Pan, Yueyin; Ma, Zhiyong; Wang, Zhehai; Fan, Min; Liu, Yunpeng; Cang, Shundong; Yang, Xinfeng; Li, Weixia; Wang, Quanren; Zhou, Caicun*复旦大学; 广州医学院; 安徽医科大学; 浙江大学; 同济大学; 中国医科大学; 1
Translational Lung Cancer Research2022-6DOI: 10.21037/tlcr-22-22
10被引15阅读
引用收藏
分享

摘要

Background: Camrelizumab plus apatinib shows encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced non-small cell lung cancer (NSCLC), however, clinical benefits from this combination regimen in NSCLC patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) have not been reported. We assessed the efficacy and safety of this combined regimen in pretreated patients with advanced NSCLC and defined EGFR/ALK status (EGFR+/ ALK+) in a phase lb/2 trial. @@@ Methods: Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily. Patients harboring sensitive EGFR mutations or ALK fusion genes had received at least one EGFR/ALK TKI and a platinum-based chemotherapy regimen before the enrollment. The primary endpoint was objective response rate (ORR). @@@ Results: All 43 enrolled patients comprised the efficacy and safety analysis population. The confirmed ORR was 18.6% (95% CI: 8.4-33.4) and the dinical benefit response rate was 27.9% (95% CI: 15.3-43.7). Median progression-free survival (PFS) was 2.8 months (95% CI: 1.9-5.5) and median overall survival was not reached (95% CI: 7.3-not reached), with a median follow-up period of 15.7 months (range, 0.5-24.4). The most common grade >= 3 treatment-related adverse events (TRAEs) were hypertension (16.3%), proteinuria (11.6%) and palmar-plantar erythrodysaesthesia syndrome (9.3%). No unexpected adverse events were recorded. @@@ Conclusions: Camrelizumab plus apatinib showed moderate antitumor activity and acceptable safety profile in previously treated patients with advanced NSCLC and EGFR or ALK genetic aberrations, which warranted further validation.

学科与关键词

关键词
CamrelizumabApatinibPD-L1 expressionimmunotherapy
相关
加载中…
  • Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
    Gao, Guanghui; Zhao, Jun; Ren, Shengxiang; Wang, Yina; Chen, Gongyan; Chen, Jianhua; Gu, Kangsheng; Guo, Renhua; Pan, Yueyin; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Zhou, Caicun*Annals of Translational Medicine, 2022, 10(8): 441.被引 11
  • Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)
    Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
  • First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*Journal for ImmunoTherapy of Cancer, 2024, 12(2): e007227.
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2022-06
卷期
第 11 卷, 第 6 期
页码
964-+
DOI
10.21037/tlcr-22-22
期刊等级
2区
成果收录
SCIE
资助标注
Jiangsu Hengrui Pharmaceuticals Co., Ltd.

作者

  • G

    Gao, Guanghui (第一作者)

    shanghai pulm hosp · tongji univ

  • N

    Ni, Jian

    shanghai pulm hosp · tongji univ

查看全部 22 位作者收起作者
  • W

    Wang, Yina

    1 · zhejiang univ

  • R

    Ren, Shengxiang

    shanghai pulm hosp · tongji univ

  • L

    Liu, Zhihua

    jiangxi canc hosp

  • C

    Chen, Gongyan

  • G

    Gu, Kangsheng

    1 · anhui med univ

  • Z

    Zang, Aimin

    hebei univ

  • Z

    Zhao, Jun

  • G

    Guo, Renhua

  • H

    He, Jianxing

    1 · guangzhou med univ

  • L

    Lin, Xiaoyan

    fujian med univ

  • P

    Pan, Yueyin

    anhui prov hosp · ustc

  • M

    Ma, Zhiyong

  • W

    Wang, Zhehai

  • F

    Fan, Min

    fudan univ

  • L

    Liu, Yunpeng

    1 · china med univ

  • C

    Cang, Shundong

    henan prov peoples hosp

  • Y

    Yang, Xinfeng

  • L

    Li, Weixia

  • W

    Wang, Quanren

  • Z

    Zhou, Caicun (通讯)

    shanghai pulm hosp · tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417